Haatch to Front Live Webinar > Smart Investing in a Post Brexit World...

By
Jeremy Luzinda
By
Haatch

Team Haatch has been hand picked to front an exclusive live webinar later this month designed to simplify start up investing in 2020.

The event, with industry experts Professional Investor will be live on February 27th and will see Haatch founder Scott Weavers-Wright sharing his view on the state of early-stage investment and the strategies that have seen the team achieve an average of 5.6x returns to date - and growing.

Speaking about the event the digital entrepreneur explained: "We've been working very hard over the last seven years to build up a reputation for smart early stage investing and Professional Investor approached us to share the secrets of our success.

"We jumped at the chance of course, and I'm really looking forward to doing so on the 27th."

The event is live online and completely free at 11am on Feb 27th. To sign up simply follow this link.

By
Jeremy Luzinda
Partner
News & Updates

The latest
‍from Haatch

See More

The AI apocalypse is happening upstairs. We work downstairs.

By
Jonathan Keeling
By
Haatch
November 6, 2026
Read more
​

AI is either about to crash the stock market or put every software company out of business, depending on the headline. Haatch Partner Jeremy Luzinda pulls the two apocalypse stories apart and explains why the drama is upstairs, while the work is down here.

​

Crediflow AI raises £1.5m to scale AI-native infrastructure for commercial credit

By
Jordan Smith
By
Haatch
November 4, 2026
Read more
​

Haatch portfolio company Crediflow AI has secured £1.5m in a round led by PXN Ventures via NPIF II, with participation from Haatch and angel investors, to automate the manual work that slows down commercial lending.

​

Virtual Science AI launches Medical Competitor AI

By
Jordan Smith
By
Haatch
October 26, 2026
Read more
​

Haatch portfolio company Virtual Science AI has launched Medical Competitor AI, its fourth product, bringing real-time competitive intelligence to pharma medical affairs teams.

​

Judged by our returns, not our size

By
Jonathan Keeling
By
Haatch
October 12, 2026
Read more
​

Why Haatch built a business beyond fundraising for fees, and why that matters for investor returns.

​